DMD060319 1906..1913

The pharmacokinetic (PK) behavior of monoclonal antibodies (mAbs) is influenced by target-mediated drug disposition, off-target effects, antidrug antibody–mediated clearance, and interaction with fragmentcrystallizable domain (Fc) receptors such as neonatal Fc receptor. All of these interactions hold the potential to impact mAb biodistribution. Near infrared (NIR) fluorescent probes offer an approach complementary to radionuclides to characterize drug disposition. Notably, the use of IRDye800 (IR800; LI-COR, Lincoln, NE) as a protein-labeling agent in preclinical work holds the potential for quantitative tissue analysis. Here, we tested the utility of the IR800 dye as a quantitative mAb tracer during pharmacokinetic analysis in both plasma and tissues using a model mouse monoclonal IgG1 (8C2) labeled with £1.5 molecules of IR800. The plasma PK parameters derived from a mixture of IR800-8C2 and 8C2 dosed intravenously to C57BL/6 mice at 8 mg/kg exhibited a large discrepancy in exposure depending on the method of quantitation [CLplasma = 8.4 ml/d per kilogram (NIR fluorescence detection) versus 2.5 ml/d per kilogram (enzyme-linked immunosorbent assay)]. The disagreement between measurements suggests that the PK of 8C2 is altered by addition of the IR800 dye. Additionally, direct fluorescence analysis of homogenized tissues revealed several large differences in IR800-8C2 tissue uptake when compared with a previously published study using [I]8C2, most notably an over 4-fold increase in liver concentration. Finally, the utility of IR800 in combination with whole body imaging was examined by comparison of IR800-8C2 levels observed in animal sagittal cross-sections to those measured in homogenized tissues. Our results represent the first PK analysis in both mouse plasma and tissues of an IR800-mAb conjugate and suggest that mAb disposition is significantly altered by IR800 conjugation to

[1]  E. Herzog,et al.  Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats. , 2014, Thrombosis research.

[2]  Li Zhang,et al.  Breast cancer sentinel lymph node mapping using near-infrared guided indocyanine green in comparison with blue dye , 2014, Tumor Biology.

[3]  L. Khawli,et al.  Quantitative cumulative biodistribution of antibodies in mice , 2014, mAbs.

[4]  D. Neri,et al.  Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications. , 2013, Bioconjugate chemistry.

[5]  L. Khawli,et al.  An integrated approach to identify normal tissue expression of targets for antibody‐drug conjugates: case study of TENB2 , 2013, British journal of pharmacology.

[6]  J. Balthasar,et al.  Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. , 2012, International journal of pharmaceutics.

[7]  P. V. van Diest,et al.  A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies , 2012, EJNMMI Research.

[8]  A. Vahrmeijer,et al.  Optical imaging of oral squamous cell carcinoma and cervical lymph node metastasis , 2012, Head & neck.

[9]  G. V. van Dongen,et al.  Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets , 2011, EJNMMI research.

[10]  Kiran Mukhyala,et al.  Effects of charge on antibody tissue distribution and pharmacokinetics. , 2010, Bioconjugate chemistry.

[11]  Theodore W Randolph,et al.  Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability. , 2009, Biochemistry.

[12]  Eva Sevick-Muraca,et al.  Characterization and performance of a near-infrared 2-deoxyglucose optical imaging agent for mouse cancer models. , 2009, Analytical Biochemistry.

[13]  P. Lambin,et al.  Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET , 2008, Journal of Nuclear Medicine.

[14]  David L. Schwartz,et al.  Imaging Epidermal Growth Factor Receptor Expression In vivo: Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe , 2008, Clinical Cancer Research.

[15]  D. Toomre,et al.  Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. , 2007, Neoplasia.

[16]  Hak Soo Choi,et al.  Real-time intraoperative ureteral guidance using invisible near-infrared fluorescence. , 2007, The Journal of urology.

[17]  J. Balthasar,et al.  Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  Joseph P. Balthasar,et al.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  M. Hashida,et al.  Pharmacokinetic analysis of in vivo disposition of succinylated proteins targeted to liver nonparenchymal cells via scavenger receptors: importance of molecular size and negative charge density for in vivo recognition by receptors. , 2002, The Journal of pharmacology and experimental therapeutics.

[20]  D. Simcoe,et al.  The Pharmacokinetics of Etanercept in Healthy Volunteers , 2000, The Annals of pharmacotherapy.

[21]  R. Jain,et al.  Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  M. Welch,et al.  Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  S. Anderson,et al.  Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. , 1991, Cellular immunology.

[24]  H. Sands Experimental studies of radioimmunodetection of cancer: an overview. , 1990, Cancer research.